An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
STAAR Surgical to Host “Vision 2026” Investor Day on September 14, 2023
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
STAAR Surgical Company to host Investor Day on September 14, 2023 in New York City.
Positive
Highlighting key company initiatives and global growth opportunities.
Positive feedback from leading refractive surgeons and EVO patients.
Negative
None.
LAKE FOREST, Calif.--(BUSINESS WIRE)--
STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses for the eye,today announced that it will host an in-person Investor Day on Thursday, September 14, 2023, beginning at 8:00 a.m. Eastern Time in New York City.
The “Vision 2026” Investor Day will highlight key company initiatives and projects including, several next generation product pipeline initiatives, as well as the significant global growth opportunities ahead for STAAR and its game-changing EVO ICL family of lenses for vision correction. Several leading refractive surgeons from around the world will speak to their experience with EVO ICL and share feedback from delighted EVO patients who no longer have to deal with the hassles of glasses and contact lenses and the reasons they chose EVO ICL.
Vision 2026, the in-person meeting, will be held at the Nasdaq MarketSite in New York and take place from 8:00 a.m. to 1 p.m. Eastern Time. Advanced registration is required for in-person attendance.
A taped replay of the event will be available at the “Investors” section of the Company’s website.
Please contact Brian Moore at bmoore@staar.com with any questions.
About STAAR Surgical
STAAR, which has been dedicated solely to ophthalmic surgery for over 40 years, designs, develops, manufactures and markets implantable lenses for the eye. These lenses are intended to provide visual freedom for patients, lessening or eliminating the reliance on glasses or contact lenses. All of these lenses are foldable, which permits the surgeon to insert them through a small incision. STAAR’s lens used in refractive surgery is called an Implantable Collamer® Lens or “ICL”, which includes the EVO ICL™ product line. More than 2,000,000 ICLs have been sold to date and STAAR markets these lenses in over 75 countries. To learn more about the ICL go to: EVOICL.com. Headquartered in Lake Forest, CA, the company operates manufacturing and packaging facilities in Aliso Viejo, CA, Monrovia, CA and Nidau, Switzerland. For more information, please visit the Company’s website at www.staar.com
staar surgical company (nasdaq: staa), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye has been dedicated solely to ophthalmic surgery for over 30 years. the company offers the evo visian implantable collamer® lenses (icls) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and hyperopic icl, which treats far-sightedness. these lenses are intended to provide visual freedom for patients, lessening or eliminating the reliance on glasses or contact lenses. all of these lenses are foldable, which permits the surgeon to insert them through a small incision. staar's lens used in refractive surgery is called an implantable collamer lens or "icl". nearly 600,000 visian icls have been implanted to date. it also provides minimally invasive intraocular lenses (iols), including foldable iols for use in minimally invasive cataract surgical procedures; aspheric iols that produce a clearer image than trad
